LabGenomics 랩지노믹스’s Post

📢 LabGenomics Establishes a Comprehensive NGS Portfolio for Cancer Reimbursement Testing, Targeting the U.S. Market LabGenomics has built a complete portfolio of next-generation sequencing (NGS) products for all selective reimbursement tests related to solid tumors and hematologic cancers. The company's NGS portfolio includes △ OTD Lung, a level 1 companion diagnostic service for non-small cell lung cancer, △ level 2 analysis service for all types of solid tumors, △ OTD Liquid, a liquid biopsy service for solid tumors, and △ HemaScan, a comprehensive analysis service for hematologic cancers. ✅ These achievements stem from the company's sustainable growth strategies, including 'Open R&D' and 'Open Innovation.' In particular, OTD Lung is praised for transforming lung cancer treatment paradigms by enabling the detection of various genetic mutations from a small sample and quickly selecting drugs within 10 days. A representative from LabGenomics' Hospital Solutions Team stated, "Unlike traditional companion diagnostic methods such as fluorescence in situ hybridization (FISH) or real-time PCR, OTD Lung can detect multiple genetic mutations in a single test, allowing for precise drug prescription. Additionally, the NGS panel-based selective reimbursement test for non-small cell lung cancer adenocarcinoma is offered at a price up to 61% lower than other cancer types, making it more affordable and driving rapid revenue growth." Since the service launch last year, the OTD Lung test results over the past year until August have shown a positive rate of 49% for drug-eligible cases, which is 2-3 times higher than the positive rates achieved with conventional real-time PCR, offering more patients treatment opportunities. ✅ The company plans to continue expanding cancer diagnostics and introduce these services to U.S. CLIA-certified labs, with the goal of boosting both scale and profitability. LabGenomics' CEO, Kim Jung-joo, emphasized, "All of our employees are committed to providing fast and accurate analysis results to give even one more cancer patient a chance for treatment. Leveraging our cancer diagnostics expertise and references accumulated over the past eight years, we will expand the 'K-Cancer Diagnosis' service into U.S. CLIA labs." 🔗 https://lnkd.in/dPkKVfpD #LabGenomics #NGS #CLIALab #OTDLung

To view or add a comment, sign in

Explore topics